Ballwin, MO, United States of America

Rory F Finn

This inventor holds 1 USPTO granted patent. Top assignee: G.d. Searle & Company. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rory F Finn. Retrieved from https://idiyas.com/inventor/rory-f-finn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Rory F Finn

Introduction

Rory F Finn is an accomplished inventor based in Ballwin, MO (US). He has made significant contributions to the field of medical technology, particularly in the area of clot lysis. His innovative work has the potential to improve treatment outcomes for patients requiring thrombolytic therapy.

Latest Patents

Rory F Finn holds a patent for the enhancement of clot lysis. This invention discloses methods and compositions for increasing clot lysis in the presence of exogenous tissue plasminogen activator. His patent represents a crucial advancement in the medical field, addressing the need for more effective treatments in managing blood clots.

Career Highlights

Rory is associated with G.D. Searle & Company, where he has been able to apply his expertise in developing innovative solutions. His work at the company has allowed him to focus on enhancing medical treatments and improving patient care.

Collaborations

Rory collaborates with Kathleen C Day, who is also a key figure in their research endeavors. Together, they work towards advancing medical technologies that can significantly impact patient health.

Conclusion

Rory F Finn's contributions to the field of medical technology through his patent on clot lysis enhancement exemplify the importance of innovation in healthcare. His work continues to pave the way for improved therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…